Mike Ouimette

Pliant Therapeutics, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Dec 24 · 0 buys · 0 salesJan 25 · 0 buys · 1 saleFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 salesNov 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (12 ops.)

€1.7M

Latest filing published 27 Jan 2025 for Pliant Therapeutics, INC..

Filing timeline

BuySale

Mike Ouimette

Insider track record

Disclosed buys

Disclosed sells

Signal history

Mike Ouimette: trading record in brief

This profile gathers the share dealings of Mike Ouimette in Pliant Therapeutics, Inc. In total, 21 filings cover trades dated from 19 December 2022 to 23 January 2025.

No open-market purchase appears, only 12 sales worth €1.7M. Other entries cover 7 share grants and 2 option exercises. So far in 2025, the count stands at no purchases and 2 sales.

Most recently, on 27 January 2025, the filings show a share grant in Pliant Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Mike Ouimette

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Pliant Therapeutics, Inc. (US)

Declarations15 total

◆
Mike Ouimette
General Counsel & Corp. Sec'yExecutives23 Jan 2025Pliant Therapeutics, Inc.
0SEC
35,000 shares0Common StockSEC:0001746473-25-000017:0
▼
Mike Ouimette
General Counsel & Corp. Sec'yExecutives17 Jan 2025Pliant Therapeutics, Inc.
148,639 USD31SEC
13,270 shares@ US$11.201116.6% of flowCommon StockSEC:0001746473-25-000001:0
▼
Mike Ouimette
General Counsel & Corp. Sec'yExecutives10 Jul 2024Pliant Therapeutics, Inc.
88,503 USD30SEC
7,656 shares@ US$11.569.4% of flowCommon StockSEC:0001746473-24-000121:0
◆
Mike Ouimette
General Counsel & Corp. Sec'yExecutives9 Jul 2024Pliant Therapeutics, Inc.
0SEC
14,954 shares0Common StockSEC:0001746473-24-000111:0
◆
Mike Ouimette
General Counsel & Corp. Sec'yExecutives23 Jan 2024Pliant Therapeutics, Inc.
0SEC
31,500 shares0Common StockSEC:0001746473-24-000015:0
▼
Mike Ouimette
General Counsel & Corp. Sec'yExecutives17 Jan 2024Pliant Therapeutics, Inc.
89,544 USD30SEC
5,197 shares@ US$17.239.5% of flowCommon StockSEC:0001746473-24-000001:0
▼
Mike Ouimette
General Counsel & Corp. Sec'yExecutives20 Jul 2023Pliant Therapeutics, Inc.
83,450 USD30SEC
4,755 shares@ US$17.558.6% of flowCommon StockSEC:0001209191-23-043085:0
▼
Mike Ouimette
General Counsel & Corp. Sec'yExecutives17 Jul 2023Pliant Therapeutics, Inc.
230,120 USD31SEC
12,778 shares@ US$18.009123.6% of flowCommon StockSEC:0001209191-23-042834:0
◆
Mike Ouimette
General Counsel & Corp. Sec'yExecutives14 Jul 2023Pliant Therapeutics, Inc.
0SEC
27,187 shares0Common StockSEC:0001209191-23-042662:0
▼
Mike Ouimette
General Counsel & Corp. Sec'yExecutives30 Mar 2023Pliant Therapeutics, Inc.
129,263 USD30SEC
4,874 shares@ US$26.520913.6% of flowCommon StockSEC:0001209191-23-022376:0
◆
Mike Ouimette
General Counsel & Corp. Sec'yExecutives29 Mar 2023Pliant Therapeutics, Inc.
0SEC
13,593 shares0Common StockSEC:0001209191-23-021927:0
◆
Mike Ouimette
General Counsel & Corp. Sec'yExecutives25 Jan 2023Pliant Therapeutics, Inc.
0SEC
39,000 shares0Common StockSEC:0001140361-23-003179:0
◇
Mike Ouimette
General Counsel & Corp. Sec'yExecutives23 Jan 2023Pliant Therapeutics, Inc.
118,600 USD12SEC
10,000 shares@ US$11.8612.6% of flowCommon StockSEC:0001140361-23-002785:0
▼
Mike Ouimette
General Counsel & Corp. Sec'yExecutives22 Dec 2022Pliant Therapeutics, Inc.
56,731 USD12SEC
2,928 shares@ US$19.37536.2% of flowCommon StockSEC:0001140361-22-046917:0
◆
Mike Ouimette
General Counsel & Corp. Sec'yExecutives19 Dec 2022Pliant Therapeutics, Inc.
0SEC
13,594 shares0Common StockSEC:0001140361-22-046568:0

15 of 15 declarations

Mike Ouimette

Insider track record

Mike Ouimette: trading record in brief

Companies and markets linked to Mike Ouimette

Related entities